Moderna (MRNA) PT Lowered to $108 at UBS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St futures rise as AI stocks catch their breath; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops more than 4% on talks aimed at ending US-Iran war
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts MRNA Hot Sheet
Price: $221.72 --0%
Rating Summary:
6 Buy, 21 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 19 | New: 16
Rating Summary:
6 Buy, 21 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 19 | New: 16
Join SI Premium – FREE
UBS analyst Eliana Merle lowered the price target on Moderna (NASDAQ: MRNA) to $108.00 (from $140.00) while maintaining a Buy rating.
You May Also Be Interested In
- William Blair Downgrades Moderna (MRNA) to Market Perform
- Moderna stock rises on latest cancer vaccine data publication
- TFI International Inc. (TFII:CN) (TFII) PT Lowered to Cdn$211 at Goldman Sachs
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
